Surmasis Reprimanded for Lab Records, Equipment Inspections

The FDA hit Surmasis Pharmaceutical of Des Moines, Iowa with a Form 483 after a February inspection revealed problems with laboratory records, computer systems and equipment inspections.
Source: Drug GMP Report